Edgewise Therapeutics, Inc. (EWTX) Cash Flow Statement

The OCF/NI ratio has declined from 1.00 in 2024Q1 to 0.76 in 2026Q2, suggesting that non-cash charges like stock-based compensation are becoming a smaller offset to cash outflows. This implies that the quality of earnings, while still negative, is deteriorating as cash burn accelerates relative to reported losses. Investors should monitor whether this trend persists as clinical trial expenses escalate.

The FCF burn has grown consistently each quarter, with the most recent quarter showing a 25% year-over-year increase. This acceleration aligns with the initiation of the GRAND CANYON pivotal trial, which likely drives higher R&D spending. Given the company's cash position of approximately $61M, the current burn rate implies a runway of under two quarters, underscoring the urgency for additional financing.

The company's capital intensity is extremely low, with quarterly CapEx never exceeding $0.5M, which is typical for a clinical-stage biotech outsourcing manufacturing. This suggests that the primary cash drain is R&D and SG&A, not fixed asset investment. The lack of significant CapEx also implies that future capital needs will be driven by clinical trial costs and potential commercialization infrastructure, which could increase substantially if the drug advances.

The working capital adjustments are small and inconsistent, reflecting the lack of inventory and receivables typical of a pre-revenue company. The positive contribution in recent quarters may be due to timing of payables, but it does not signal operational efficiency. Investors should not expect working capital to be a meaningful source of cash in the near term.

The absence of capital returns is expected for a clinical-stage company, but it highlights that shareholder value depends entirely on pipeline success. The increasing R&D spend, up 101% from 2024Q1, indicates management's commitment to advancing EDG-5506, but it also raises the stakes for positive trial outcomes. With no acquisitions or debt paydown, the balance sheet remains clean, but the company will likely need to raise equity soon.

The gap between net income and operating cash flow is primarily due to stock-based compensation, which is a non-cash expense that reduces reported losses but does not consume cash. This divergence suggests that the company's cash burn is actually lower than accounting losses, but the trend is narrowing as SBC becomes a smaller proportion of total costs. Investors should focus on cash burn as the more accurate measure of sustainability, especially as the company approaches pivotal data readouts.